Embera NeuroTherapeutics, Inc.' Lead Candidate, EMB-001, Supported by $3.9M Grant from National Institute on Drug Abuse (NIDA)

SHREVEPORT, La. & BOSTON--(BUSINESS WIRE)--Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera’s drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing. Work done under this grant will also support Embera’s clinical development program for EMB-001 for smoking cessation.